A bivalent cyclic RGD–siRNA conjugate enhances the antitumor effect of apatinib via co-inhibiting VEGFR2 in non-small cell lung cancer xenografts

The vascular endothelial growth factor receptor 2 (VEGFR2) is considered to be a pivotal target for anti-tumor therapy against angiogenesis of non-small cell lung cancer (NSCLC). However, effective and low-toxicity targeted therapies to inhibit VEGFR2 are still lacking. Here, biRGD–siVEGFR2 conjugat...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Drug Deliv
Prif Awduron: Liao, Lumin, Cen, Bohong, Li, Guoxian, Wei, Yuanyi, Wang, Zhen, Huang, Wen, He, Shuai, Yuan, Yawei, Ji, Aimin
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Taylor & Francis 2021
Pynciau:
Research Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC8274511/
https://ncbi.nlm.nih.gov/pubmed/34236267
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10717544.2021.1937381
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg